Corcept Therapeutics
CORT
367 hedge funds and large institutions have $4.25B invested in Corcept Therapeutics in 2024 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 116 increasing their positions, 124 reducing their positions, and 30 closing their positions.
170% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 30
14% more funds holding
Funds holding: 321 → 367 (+46)
4% more capital invested
Capital invested by funds: $4.09B → $4.25B (+$153M)
6% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 124
4.24% less ownership
Funds ownership: 84.66% → 80.42% (-4.2%)
21% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $73.7M
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$18.5M |
| 2 |
BSA
Braun Stacey Associates
New York
|
+$15.5M |
| 3 |
Millennium Management
New York
|
+$14.1M |
| 4 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
+$13.8M |
| 5 |
Goldman Sachs
New York
|
+$8.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$112M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$32.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$23.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$22.3M |
| 5 |
BlackRock
New York
|
-$19.5M |
CORT Hedge Fund Activity: Q4 2024 in Review
367 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2024, worth a combined $4.25B — up 3.7% from $4.09B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new CORT positions and 30 closed out — a net gain of 51 holders — while 116 added to existing stakes and 124 trimmed.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $18.5M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $112M sold.
- 367 institutional investors held Corcept Therapeutics (CORT) as of Q4 2024, up from 321 in Q3 2024.
- Funds reported $4.25B of Corcept Therapeutics stock for Q4 2024, up 3.7% quarter-over-quarter.
- 81 funds opened new Corcept Therapeutics positions in Q4 2024 and 30 closed out, a net change of +51 holders.
- The largest Corcept Therapeutics buyer in Q4 2024 was Qube Research & Technologies (QRT), an estimated $18.5M added.
- The largest Corcept Therapeutics seller in Q4 2024 was Novo Holdings A/S, an estimated $112M sold.
Based on aggregated 13F filings for Q4 2024.